Murat Albayrak

Dışkapı Yıldırım Beyazıt Training and Research Hospital, Engüri, Ankara, Turkey

Are you Murat Albayrak?

Claim your profile

Publications (11)9.19 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to establish the protective effect of caffeic acid phenethyl ester (CAPE) against the ifosfamide (IFOS)-induced central neurotoxicity in rats and to determine the changes in oxidant-antioxidant status of brain tissue. Method: A total of 35 Wistar rats (aged 7-12 days) were used in the experiments. The study comprised of five groups. Control untreated rats (n = 7) belonged to group 1; group 2 was given intraperitoneal (IP) injection of CAPE alone (10 µmol/kg; n = 7); group 3 was treated with single IP injection of IFOS (500 mg/kg; n = 7); group 4 was treated for 2 days with IP administration of CAPE (10 µmol/kg) beginning from one day before single IP injection of IFOS (n = 7); and group 5 was treated with saline and 10% ethanol. At the 24th hour of IFOS treatment, brain tissues were removed for analysis. The brain catalase activity was lower in IFOS group than the other groups (p < 0.05). The levels of malondialdehyde (MDA) and protein carbonyl content in brain tissue were higher in IFOS group than the control, CAPE, ethanol, and IFOS + CAPE groups (p < 0.05). There was no significant difference between MDA and protein carbonyl content of control, CAPE, ethanol, and IFOS + CAPE groups. Immunohistochemistry showed marked activation of caspase 3 in the IFOS group at 24 h after treatment. This study revealed that pretreatment with CAPE might protect brain tissue against IFOS-induced central neurotoxicity. CAPE could be an effective course of therapy to enhance therapeutic efficacy and to lessen IFOS toxicity in clinical chemotherapy.
    Toxicology and Industrial Health 10/2013; · 1.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin converting enzyme (ACE) is a circulating enzyme that participates in the body's renin-angiotensin system (RAS) and is localized on the endothelial cell surface in the lung and other vascular beds. It catalyses the conversion of decapeptide angiotensin I to octapeptide angiotensin II. In the present study, we aimed to analyse the possible relationship between the levels of ACE in the context of RAS in multiple myeloma (MM) pathogenesis. The study was conducted on 25 MM patients (13 males, 12 females; median age 66 years, range 47-88) and 20 healthy controls. The clinical features of MM patients including demographics and laboratory findings were summarized. Serum ACE levels were measured by using commercially available kits. The serum ACE levels of MM patients and controls were 32.60±20.26 and 15.35±6.47 respectively. Serum ACE levels were significantly higher in MM patients compared with control groups (p<0.001). Being an important component of RAS, circulating ACE might be associated with clonal proliferation of malignant plasma cells in the bone marrow microenvironment. Identification of the pathobiological activity of the local RAS in MM would enlighten the biologic basis and clinical management of haematologic disorders.
    Journal of Renin-Angiotensin-Aldosterone System 02/2012; 13(2):259-64. · 2.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AIM: In addition to suppressing fibrinolysis, thrombin activatable fibrinolysis inhibitor (TAFI) was suggested to be involved in inflammation. To date, no study has been published that reports the role of TAFI in acute pancreatitis (AP). Therefore, the objective of the present study was to investigate the role of plasma TAFI as an indicator of inflammation in AP, and its association with disease severity. METHODS: Plasma TAFI antigen levels quantitatively determined by using ELISA kits in 21 AP patients at onset and remission and 17 healthy controls. Associations of TAFI with inflammatory markers to determine AP and disease severity were assessed. To predict the severity of AP, modified Glasgow prognostic score (mGPS) and computerized tomography severity index (CTSI) were used for each subject. RESULTS: Plasma TAFI levels was higher in AP patients at onset of the disease compared with healthy controls. The disease severity according to mGPS was significantly correlated with TAFI levels. Overall, accuracy of TAFI in determining AP was 83.3% with a sensitivity, specificity, NPV and PPV of 80.9%, 85.7%, 81.8%, and 85% respectively (AUC: 0.915). CONCLUSIONS: The present study for the first time demonstrated that TAFI is elevated in AP. The appraisal of TAFI levels in patients with AP in conjunction with other markers of inflammation may provide additional information in estimating AP severity.
    Gastroentérologie Clinique et Biologique 01/2012; · 0.80 Impact Factor
  • Acta gastro-enterologica Belgica 12/2011; 74(4):585-6. · 0.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma has been associated with the development of thromboembolic events. Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme, which potently inhibits fibrinolysis. The purpose of the present study was to assess the TAFI levels in patients with newly diagnosed multiple myeloma. Twenty-seven newly diagnosed multiple myeloma patients (16 women and 11 men) and 27 age-matched healthy individuals (14 women and 13 men) were included in the study. Serum TAFI levels were significantly increased in patients with multiple myeloma (46 ± 13. 3 vs. 36. 6 ± 9.7 μg/ml) compared with healthy individuals. Serum TAFI levels were negatively correlated with serum albumin (CC: -0.453, P < 0.05) and hemoglobin levels (CC: -0.392, P < 0.05) and positively correlated with the β-2 microglobulin levels (CC: 0.524, P < 0.05). In this study, we observed significantly elevated TAFI levels in patients with multiple myeloma and higher serum TAFI levels were suggested to be associated with higher disease stage. With these results, a possible role of elevated TAFI levels in thromboembolic manifestations in the course of multiple myeloma can be suggested.
    Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis 02/2011; 22(4):260-3. · 1.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this case report we overview the diagnostic and therapeutic approaches for pleural effusions encountered during the tre-atment and follow-up of patients with myeloma in the light of the current medical literature. A 73-year-old female patient with a stage IIIA multiple myeloma was being treated with melphalan and methyl prednisolone. In the third month of the treat-ment, she had complaints of coughing, dyspnea and right side pain. Computed tomographic examination of the thorax re-vealed pleural effusion. Pathological examinations of the pleural fluid and pleural biopsy specimen were compatible with ade-nocarcinoma. Repeated examinations did not reveal a progression in myeloma or a pleural involvement of myeloma. The pa-tient died of respiratory insufficiency due to the progression of the pleural adenocarcinoma.
    01/2011;
  • Pathology & Oncology Research 01/2011; 17(2):421-3. · 1.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The increased risk for thrombosis is known as hypercoagulability or thrombophilia. Here, we investigated risk factors for thrombophilia which were screened in young adult patients presenting with thrombotic events or with recurrent abortions with unknown etiology. A total of 115 patients aged between 16 and 50 years who were found to harbor thrombophilia were retrospectively evaluated. The laboratory investigations performed for the assessment of thrombophilia included protein C, protein S, antithrombin III deficiencies, activated protein C resistance, factor V Leiden (FVL), prothrombin 20210A (PT 20210) and methylenetetrahydrofolate reductase (MTHFR) gene mutations, factor VIII elevation, lupus anticoagulant and antiphospholipid antibodies (APA). In 66% of the cases a single thrombophilic defect was identified while some of the patients had combined thrombophilic defects. The most common thrombophilic defect was mutation in the MTHFR gene, and was followed by FVL mutation, the presence of APA and PT 20210 gene mutation, respectively. The patients were divided into two different age groups, 16-35 and 36-50 years, and arterial thrombosis was more common in the older age group. Our results indicated that some important thrombophilic defects such as gene mutations may appear in young adult patients presenting with thrombotic events.
    International journal of hematology 11/2009; 90(5):583-90. · 1.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ankaferd Blood Stopper (ABS) is a novel topical hemostatic agent. ABS-induced formation of the protein network with vital erythro-id aggregation covers the entire physiological hemostatic process. ABS has pleiotropic cellular, proteomic, transcriptomic, and me-tabolomic effects. ABS also affects the expression of important hemostatic molecules namely PAR-1, EPCR and PAI-1. The aim of this study was to detect the macroscopic, biochemical, and cytopathological effects of ABS on myeloma monoclonal immunoglo-bulin (M-protein). Based on our results, the addition of ABS into the serum of both multiple myeloma (MM) and control groups resul-ted in significantly decrements in the level of total protein, albumin, IgG, IgA and IgM. Furthermore, the decrements in the MM pati-ents were more pronounced than in the healthy control subjects. ABS has a potential role in decreasing of serum proteins and mo-noclonal M-proteins. Moreover, the declining in the neoplastic monoclonal M-protein was more prominent. We hypothesized that ABS could be used as an "agglutination-controlling factor" for myeloma monoclonal proteins and the protein-aggregating effects of ABS may be helpful for expressing the regulatory molecules promoting or preventing the myeloma protein aggregation. ÖZET Ankaferd Hemostat ile ‹n Vitro Myelom Monoklonal ‹mmünglobulin Agregasyonunun Belirgin Art›fl› Ankaferd Blood Stopper (ABS) yeni bir topikal hemostatic ajand›r. ABS taraf›ndan indüklenen protein a¤› oluflumu hayati eritroid ag-regasyonu ile birlikte tüm fizyolojik hemostatik süreci kapsar. ABS hücresel pleiotropik, proteomik, transkriptomik ve metabolik etki-lere sahiptir. ABS ayn› zamanda PAR-1, EPCR ve PAI-1 gibi önemli hemostatik moleküllerin ekspresyonunu da etkiler. Bu çal›flma-n›n amac›; ABS'nin miyelom monoklonal immünoglobulini (M-protein) üzerindeki makroskopik, biyokimyasal ve sitopatolojik etkilerini saptamakt›. Sonuçlar›m›za göre, hem multiple myelom (MM) hem de kontrol gruplar›n›n serumlar›na ABS ilavesi total protein, albu-min, IgG, IgA ve IgM seviyelerinde belirgin bir azalmayla sonuçland›. Ek olarak, MM hastalar›nda görülen azalma sa¤l›k-l› kontrol grubundakilerden daha belirgindi. ABS serum proteinlerinin ve monoklonal M-proteinlerinin azalmas›nda potansiyel bir role sahiptir. Ayr›ca neoplastik monoklonal M-proteinlerindeki azalma daha da belirgindi. Hipotezimize göre, ABS miyelom monoklonal proteini için ''agglütinasyonu control eden faktör''olarak kullan›labilir ve ABS'nin proteinleri aglütine edici etkisi, miyelom protein ag-regasyonunu önleyen veya artt›ran düzenleyici moleküllerin ekspresyonunda yard›mc› olabilir.
    01/1999;
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we evaluated the plasma levels of endostatin (PE) and its prognostic importance in patients with acute myeloblastic (AML) and lypmhoblastic leukemia (ALL). We therefore analyzed plasma levels of endostatin before the chemotherapy and during the complete remission period in adult ALL and AML patients. The PE levels of the control group were significantly lower than both ca-ses with ALL and AML. The patients with AML during remission had significantly higher PE levels than the levels at initial diagnosis. No statistically significant difference was detected in patients with ALL. In addition, the survival rates of the cases with ALL whose PE levels are higher than 2.5 ng/ml, are significantly lower. Our results suggest that the elevated plasma levels of endostatin during the remission in patients with AML imply the intensity of angiogenesis inhibition during the remission. Furthermore our findings in ALL patients suggest that endostatin levels may predict the overall survival of these patients. ÖZET Akut Myeloblastik ve Lenfoblastik Lösemili Hastalarda Plazma Endostatin Düzeylerinin De¤erlendirilmesi Bu çal›flmada akut myeloblastik (AML) ve akut lenfoblastik lösemili (ALL) hastalarda plazma endostatin (PE) düzeylerini ve prognos-tik anlam›n› de¤erlendirdik. Bu amaçla eriflkin ALL ve AML hastalar›nda kemoterapi öncesi ve komplet remisyon s›ras›nda plazma en-dostatin düzeylerini analiz ettik. Kontrol grubunun plazma endostatin (PE) düzeyi hem ALL hem de AML hastalar›na göre istatistiksel olarak anlaml› oranda daha düflüktü. AML'li hastalarda remisyon s›ras›ndaki PE düzeyleri tan› an›na göre anlaml› olarak daha yük-sekti, ALL'li hastalarda istatistiksel olarak anlaml› bir fark tespit edilmedi. Ayr›ca 2,5 ng/ml'nin üzerinde PE düzeylerine sahip ALL has-talar›nda yaflam süresi anlaml› olarak daha düflüktü. AML olgular›nda remisyon s›ras›nda endostatin düzeylerinin yüksek olmas› re-misyon sürecinde anjiogenez inhibisyonunun yo¤unlu¤unu gösterebilir. Ayr›ca bulgular›m›z ALL'de endostatin düzeylerinin toplam ya-flam süresini ön görmede etkili olabilece¤ini düflündürmüfltür.

Publication Stats

13 Citations
9.19 Total Impact Points

Institutions

  • 2012
    • Dışkapı Yıldırım Beyazıt Training and Research Hospital
      Engüri, Ankara, Turkey
  • 1999–2011
    • Ankara Children's Hematology Oncology Training and Research Hospital
      Engüri, Ankara, Turkey